Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Management of cT4 Prostate Cancer.

Ranasinghe WKB, Reichard CA, Bathala T, Chapin BF.

Eur Urol Focus. 2019 Jun 29. pii: S2405-4569(19)30167-1. doi: 10.1016/j.euf.2019.06.012. [Epub ahead of print] Review.

PMID:
31266732
2.

The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.

Gunner C, Gulamhusein A, Rosario DJ.

J Clin Urol. 2016 Dec;9(2 Suppl):24-29. doi: 10.1177/2051415816654048. Epub 2016 Dec 1.

3.

Management strategies for locally advanced prostate cancer.

Jani AB.

Drugs Aging. 2006;23(2):119-29. Review.

PMID:
16536635
4.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
6.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
7.

Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.

Moreau JP, Delavault P, Blumberg J.

Clin Ther. 2006 Oct;28(10):1485-508. Review. Erratum in: Clin Ther. 2006 Nov;28(11):1970.

PMID:
17157109
8.

The role of radiotherapy in localised and locally advanced prostate cancer.

Bolla M, Henry A, Mason M, Wiegel T.

Asian J Urol. 2019 Apr;6(2):153-161. doi: 10.1016/j.ajur.2019.02.001. Epub 2019 Feb 8. Review.

9.

[Radiation therapy of locally advanced prostate cancer].

Schmidt-Hegemann NS, Li M, Eze C, Belka C, Ganswindt U.

Urologe A. 2017 Nov;56(11):1402-1409. doi: 10.1007/s00120-017-0511-4. Review. German.

PMID:
28983664
10.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.

Lancet Oncol. 2019 Feb;20(2):267-281. doi: 10.1016/S1470-2045(18)30757-5. Epub 2018 Dec 19.

PMID:
30579763
11.

Locally advanced prostate cancer: current controversies and optimisation opportunities.

Sridharan S, Dal Pra A, Catton C, Bristow RG, Warde P.

Clin Oncol (R Coll Radiol). 2013 Aug;25(8):499-505. doi: 10.1016/j.clon.2013.04.004. Epub 2013 May 13. Review.

PMID:
23680106
12.

[Current treatment of locally advanced and metastatic prostate cancer].

Ponholzer A, Steinbacher F, Madersbacher S, Schramek P.

Wien Med Wochenschr. 2011 Aug;161(15-16):377-81. doi: 10.1007/s10354-011-0014-7. Review. German.

PMID:
21953428
13.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
14.

Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer.

Golabek T, Belsey J, Drewa T, Kołodziej A, Skoneczna I, Milecki P, Dobruch J, Słojewski M, Chłosta PL.

Cent European J Urol. 2016;69(2):131-8. doi: 10.5173/ceju.2016.812. Epub 2016 Jun 20. Review.

15.

Medical therapy of prostate cancer. A review.

Roscigno M, Sangalli M, Mazzoccoli B, Scattoni V, Da Pozzo L, Rigatti P.

Minerva Urol Nefrol. 2005 Jun;57(2):71-84. Review.

PMID:
15951731
16.

Treatment of locally advanced prostate cancer: is chemotherapy the next step?

Oh WK, Kantoff PW.

J Clin Oncol. 1999 Nov;17(11):3664-75. Review.

PMID:
10550165
17.

Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).

Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, Warnack W, Persad R, Salagierski M, Gómez Veiga F, Baskin-Bey E, López B, Tombal B.

Eur Urol. 2016 Apr;69(4):720-727. doi: 10.1016/j.eururo.2015.10.007. Epub 2015 Oct 29.

18.

Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.

Dell'Oglio P, Abou-Haidar H, Leyh-Bannurah SR, Tian Z, Larcher A, Gandaglia G, Fossati N, Shariat SF, Capitanio U, Briganti A, Montorsi F, Graefen M, Saad F, Karakiewicz PI.

Eur Urol. 2016 Sep;70(3):429-35. doi: 10.1016/j.eururo.2016.02.057. Epub 2016 Mar 4.

PMID:
26951945
19.

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C.

Lancet Oncol. 2011 May;12(5):451-9. doi: 10.1016/S1470-2045(11)70063-8.

PMID:
21440505
20.

Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.

Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S.

Eur Urol Oncol. 2019 Mar;2(2):174-188. doi: 10.1016/j.euo.2018.09.005. Epub 2018 Oct 9. Review.

PMID:
31017094

Supplemental Content

Support Center